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Abstract: Introduction: Myelodysplastic syndromes (MDS) are characterized by bone marrow failure
due to disturbed bone marrow maturation. MDS is associated with increased risk of transformation
to acute myeloid leukemia (AML) and features of immunological dysregulation. Materials and
methods: Serum levels of 47 soluble immune mediators were examined in samples derived from
49 MDS patients (35 low-risk and 14 high-risk) and 23 healthy adults. Our patients represent
an unselected population-based cohort. The mediators included cytokines, soluble adhesion proteins,
matrix metalloproteases, and tissue inhibitors of proteases. Levels were determined using Luminex
assays. Patients were classified as low- and high-risk based on the international prognostic scoring
system (IPSS) score. Results: When comparing the serum levels of single mediators the MDS patients
showed a relatively wide variation range for several mediators compared with healthy adults,
especially interleukin 6 (IL-6), IL-8/CXCL8, CCL3, and CCL4. The high-risk patients had lower levels
of epidermal growth factor (EGF), cluster of differentiation 40 ligand (CD40L), CCL5, CCL11, CXCL5,
matrix metalloproteinase 1 (MMP-1), MMP-9, and tissue inhibitor of metalloproteinases 2 (TIMP-2)
compared with low-risk patients. Unsupervised hierarchical cluster analysis visualized marked
serum mediator profile differences between MDS patients; based on this analysis three patient subsets
could be identified. The healthy adults were also included in this analysis and, as expected, they
formed their own separate cluster, except for one outlier. Both low- and high-risk patients showed
considerable heterogeneity with regard to serum profile, and this heterogeneity seems stable over
time (one year follow-up). Finally, very few mediators differed between low- and high-risk patients,
but hierarchical clustering based both on all mediators, as well as five selected mediators (EGF,
CCL11, TIMP-2, MMP-1, and MMP-9) identified subsets of patients with significantly increased
frequency of high-risk disease (χ-square test p = 0.0158 and p = 0.0148).
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1. Introduction
Myelodysplastic syndromes (MDS) are a group of bone marrow disorders characterized by
dysplastic maturation of bone marrow cells, reduced levels of mature myeloid cells in peripheral
blood, and increased risk of transformation to acute myeloid leukemia (AML) [1,2]. MDS can be
divided into four different subsets based on the international prognostic scoring system (IPSS), and
based on this scoring patients can be classified as low-risk (low and intermediate 1 IPSS classes)
and high-risk (intermediate 2 and high risk IPSS classes) [3]. The bone marrow in low-risk MDS is
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characterized by increased apoptosis, whereas high-risk patients are characterized by accumulation of
apoptosis-resistant blasts in bone marrow and, eventually, peripheral blood.
The immune system is postulated to play an important role in the pathophysiology of MDS, at
least in a subset of the patients [4–7]. Low-risk MDS is dominated by proinflammatory cells, while
immunosuppressive cells (regulatory T cells and myeloid-derived suppressor cells) [8,9] are more
important in high-risk disease where they possibly provide immune evasion for MDS blasts and aid in
transformation to AML. The bone marrow environment is important for normal maturation of bone
marrow progenitor cells, and signaling through direct cell contact, as well as soluble mediators, are
both necessary for correct maturation of progenitor cells [10,11]. Thus, investigation of systemic (i.e.,
serum or plasma levels) of soluble mediators may reveal information regarding the pathophysiology
in MDS, e.g., immunoregulation, as well as regulation of hematopoiesis.
Systemic cytokine profiles (plasma or serum levels) in MDS patients have been investigated in
relatively few previous studies [12–14]. Kornblau et al. [12] investigated serum levels of cytokines
and chemokines for AML and MDS patients. They found major similarities regarding cytokine levels
between these two groups, but large differences compared to healthy controls. Feng et al. [13] found
increased plasma levels of tumor necrosis factor α (TNFα), interleukin 6 (IL-6), CCL3, interleukin
1 receptor α (IL-1ra), hepatocyte growth factor (HGF), and CCL4 in MDS compared to patients with
aplastic anemia (AA) and healthy controls. Epidermal growth factor (EGF) and CXCL5 were then
lower in AA as well as MDS compared to controls, whereas only CCL2 was lower in aplastic anemia
when compared to MDS. A third study by Pardanani et al. [14] found increased plasma levels of a wide
range of cytokines/chemokines in MDS patients compared to healthy controls. Pardanani et al. [14]
did not find any significant differences between high- and low-risk MDS, while Feng et al. [13]
observed increased CCL4 levels and decreased levels of CCL5, CXCL5, cluster of differentiation
40 ligand (CD40L), vascular endothelial growth factor (VEGF), and EGF in high-risk MDS compared
to low-risk disease. This discrepancy calls for further exploration into the cytokine profiles in low- and
high-risk MDS. Additionally, these studies did not combine a broad cytokine/chemokine profiling
with investigation of biologically different, but functionally related, mediators (i.e., soluble adhesion
molecules, proteases, protease inhibitors). For these reasons we have investigated the serum levels of
a wide range of biologically diverse, but functionally interacting, soluble mediators (including several
cytokines) in a large group of unselected MDS patients.
2. Results
2.1. The Serum Levels of Single Mediators Show a Wide Variation between Myelodysplastic Syndromes
(MDS) Patients
We compared the serum cytokine levels for MDS patients and a group of healthy adults.
Our controls were younger than the MDS patients. However, Feng et al. [13] could not detect any
age-dependent variation in the systemic levels for any of the cytokines included in our present study,
and this has later been confirmed by others for a large number of these cytokines [15]. It is not known
whether systemic levels of soluble adhesion molecules, matrix metalloproteases, or tissue inhibitors
show any age-dependent variation. For these reasons Table 1 only includes the comparison of systemic
cytokine levels for MDS patients and healthy adults, whereas the comparisons for the other mediators
are not shown. We used the Mann–Whitney U test for these statistical analyses. The patients showed
increased levels of several interleukins (IL-5 p < 0.001, IL-6 p = 0.013, IL-8/CXCL8 p < 0.001, IL-13
p = 0.001) and chemokines (CCL3 p < 0.001, CXCL10 p < 0.001), whereas they showed decreased
levels for one interleukin (IL-10 p < 0.001), two chemokines (CCL5 p = 0.010, CXCL5 p < 0.001), two
immunoregulatory cytokines (interferon γ (IFNγ) p < 0.001, CD40L p = 0.013), and one growth factor
(thrombopoeitin (TPO) p < 0.001). Most of these differences were still significant after Bonferroni
correction (p < 0.0015). Thus, the differences in systemic mediator profiles include a wide range of
biologically different cytokines.
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Table 1. Serum levels of soluble mediators; a comparison between myelodysplastic syndromes (MDS)
patients and healthy individuals.
Mediator MDS Patients Healthy Individuals p-Value
Cytokines
IL-1ra 761 (182–10,311) 852 (503–1700) <0.001
IL-1α 5.04 (bd–241) n/a n/a
IL-1β * bd (bd–6.99) n/a n/a
IL-4 bd (bd–51.4) bd (bd–29.5) ns
IL-5 4.17 (bd–16.3) bd (bd–1.57) <0.001
IL-6 * 5.85 (bd–88.7) 3.47 (bd–5.23) 0.013
IL-10 * bd (bd–22.8) 3.87 (2.62–5.33) <0.001
IL-13 bd (bd–362) bd (bd–66.7) 0.001
Chemokines
CCL2 * 276 (bd–1570) 268 (146–632) ns
CCL3 113 (bd–6370) 55.2 (bd–137) <0.001
CCL4 * 66.0 (bd–6320) 64.7 (14.0–150) ns
CCL5 ad (134–ad) ad (5060–ad) 0.010
CCL11 136 (bd–283) 114 (30.4–500) ns
CXCL5 566 (bd–5700) 1 590 (425–4200) <0.001
CXCL8 * 41.0 (8.10–1220) 14.5 (1.69–37.8) <0.001
CXCL10 * 59.0 (7.00–590) 17.1 (9.16–57.6) <0.001
CXCL11 * 40.5 (bd–2690) bd (bd–167) ns
Immunomodulatory cytokines
TNFα 2.01 (bd–24.9) 3.17 (bd–17.8) ns
IFNγ * bd (bd–6.97) 2.94 (bd–3.57) <0.001
CD40L * 3940 (264–27,300) 7560 (4470–22,600) 0.013
Growth factors
EGF * 73.4 (bd–283) 80.1 (40.2–222) ns
VEGF * 86.5 (bd–275) 84.2 (10.4–264) ns
TPO 467 (110–2058) 779 (174–1057) <0.001
HGF 275 (31.0–1605) 385 (175–545) ns
G-CSF * 33.9 (bd–140) 25.6 (bd–71.3) ns
Leptin 4750 (622–148,000) 10,500 (1400–46,600) ns
Adhesion molecules; serum levels in MDS patients
E-Selectin 28,400 (6770–107,000) ICAM-1 272,000 (84,100–589,000)
P-Selectin 56,200 (18,100–126,000) VCAM-1 1,220,000 (552,000–4,540,000)
Matrix metalloproteinases and inhibitors; serum levels in MDS patients
MMP-1 3570 (184–14,800) MMP-12 8.50 (bd–38.3)
MMP-2 45,800 (36,000–62,500) TIMP-1 166,000 (91,000–257,000)
MMP-3 12,500 (2720–17,800) TIMP-2 108,000 (57,400–248,000)
MMP-7 4810 (993–31,100) TIMP-3 27,400 (bd–77,400)
MMP-8 4260 (350–35,600) TIMP-4 2080 (1110–4170)
MMP-9 8110 (1040–74,700)
All mediators are given as pg/mL. The Mann–Whitney U test is used for comparison between the two groups
for each mediator, and the corresponding p-values still significant after Bonferroni correction are given in
bold (p-values < 0.0015). Fibroblast growth factor basic (FGF-B), granulocyte macrophage colony-stimulating
factor (GM-CSF), interleukin 2 (IL-2), IL-12, IL-17, and matrix metalloproteinase 13 (MMP-13) are not included
in the table as all or most serum levels of these mediators were undetectable. Serum levels of IL-1α, IL1-β,
MMP-12, and tissue inhibitors of metalloproteinases 1-4 (TIMP1-4) were only investigated for MDS patients.
ad; above detection level; bd, below detection level; n/a, not available; ns, not significant; tumor necrosis
factor (TNF); interferon (IFN), cluster of differentiation 40 ligand (CD40L); epidermal growth factor (EGF);
vascular endothelial growth factor (VEGF); thrombopoietin (TPO); hepatocyte growth factor (HGF); granulocyte
colony-stimulating factor (G-CSF); intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule
1 (VCAM-1). * A previous study could not detect any age-dependent differences for these mediators except for
CD40L that showed higher levels in elderly individuals, while G-CSF and CCL2 showed lower levels in elderly
individuals [15].
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It can be seen from Table 1 that a relatively wide variation range was detected for many of
the cytokines compared with the healthy controls. The systemic levels of many soluble adhesion
molecules, matrix metalloproteases, and tissue inhibitors of matrix proteases also showed a wide
variation between the patients.
Most of the significant differences noted above from comparing all MDS patients with controls
were also detected when comparing high- and low-risk patients separately with the healthy adults
(data not shown). Only four mediators varied differently for high- and low-risk MDS patients; CXCL11
was significantly decreased only for low-risk patients compared to controls (p = 0.014) whereas CD40L
(p = 0.003) and EGF (p = 0.008) were decreased only for the high-risk patients. Thus, for the majority of
cytokines similar differences were detected when high- and low-risk MDS patients were compared
with healthy individuals.
Previous studies have described that age can influence the systemic mediator levels also for
patients with myeloid malignancies [16]. However, only CXCL5 (n = 49. r = 0.343, p = 0.017), MMP-3
(r = 0.422, p = 0.003), TIMP-2 (r = 0.362, p = 0.011), and TIMP-4 (r = 0.506, p < 0.001) showed significant
correlations with age for our MDS patients. MMP-1, MMP-3, MMP-8, MMP-9, TIMP-3, and P-selectin
all showed positive correlation to both absolute neutrophil and lymphocyte counts (data not shown).
We could not detect any correlation between age and the systemic levels of soluble adhesion
molecules, MMPs or TIMPs for our healthy controls, and for this reason we used the comparison
between MDS patients and healthy controls to illustrate that these mediator levels also showed
a considerable variation between patients. The following differences were then observed:
‚ The patient P-selectin levels were significantly lower than the corresponding levels in the healthy
controls (median control levels 83,100 pg/mL, range 43,800–112,000 pg/mL; p = 0.001), whereas the
patient levels of intercellular adhesion molecule 1 (ICAM-1) (median control level 146,000 pg/mL,
range 76,100–329,000 pg/mL, p < 0.001) and vascular cell adhesion molecule 1 (VCAM-1) (median
control level 652,000 pg/L, range 342,000–1,580,000, p < 0.001) were increased. Furthermore,
the patient levels did not show any significant correlation with age for any of these soluble
adhesion molecules.
‚ The patient levels were significantly lower than corresponding levels in healthy controls for
MMP-2 (median control level 180,000 pg/mL, range 54,400–248,000 pg/mL, p < 0.001), MMP-3
(median control level 39,500 pg/mL, range 4600–160,000 pg/mL, p < 0.001), MMP-8 (median
control level 6380 pg/mL, range 1708–12,100 pg/mL, p = 0.039), and MMP-9 (median control
level 115,000 pg/mL, range 42,900–333,000 pg/mL, p < 0.001). In contrast, the patients showed
increased MMP-7 levels compared with the controls (median control level 2060 pg/mL, range
944–8930 pg/mL, p < 0.001). Only MMP-3 showed a correlation with age for the MDS patient group.
2.1.1. Serum Mediator Profiles Differ Slightly between High- and Low-Risk MDS Patients
MDS is a heterogeneous disease and the inflammatory state seems to differ between low- and
high-risk patients [5,17,18]. We, therefore, compared serum levels of cytokines, growth factors,
adhesion molecules, and proteases/protease inhibitors between the high- and low-risk MDS patient
groups (Table 2). Patients with high-risk MDS had lower serum levels of EGF (Mann–Whitney U test,
p = 0.011), CD40L (p = 0.006), CCL5 (p = 0.001), CCL11 (p = 0.012), and CXCL5 (p = 0.004) compared
to the low-risk patients (Figure 1). The levels of MMP-1 (p = 0.003) and MMP-9 (p = 0.010), as well
as the inhibitor TIMP-2 (p = 0.006), were also lower in high-risk patients (Figure 1). However, CCL5
was the only mediator which retained significance using Bonferroni-corrected p-values (p < 0.0013).
Differences found based on high- and low-risk were confirmed when comparing patients with blast
counts below and above five percent, with the exception of CCL11 and MMP-9, which were present
in similar levels between the two groups (EGF p = 0.002, CD40L p = 0.001, CCL5 p = 0.004, CCL11
p = 0.213, CXCL5 p = 0.001, MMP-1 p = 0.002, MMP-9 p = 0.059, and TIMP-2 p = 0.001). Thus, high-risk
MDS patients show decreased serum levels of a subset of biologically heterogeneous soluble mediators
compared to low-risk patients.
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Table 2. Serum levels of soluble mediators; a comparison between low- and high-risk MDS patients.
Mediator Low-Risk MDS High-Risk MDS p-Value
Cytokines
IL-1ra 665 (318–4610) 1032 (182–10,300) ns
IL-1α 2.75 (bd–241) 23.9 (bd–203) ns
IL-1β bd (bd–6.99) 0.87 (bd–4.04) ns
IL-4 bd (bd–46.0) bd (bd–51.4) ns
IL-5 bd (bd–16.3) 4.55 (bd–16.1) ns
IL-6 5.55 (bd–39.2) 5.85 (bd–88.7) ns
IL-13 bd (bd–292) 103 (bd–362) ns
Chemokines
CCL2 276 (bd–1570) 268 (146–632) ns
CCL3 113 (bd–6370) 55.2 (bd–137) ns
CCL4 66.0 (bd–6320) 64.7 (14.0–150) ns
CCL5 ad (2010–ad) ad (134–ad) 0.001
CCL11 136 (bd–283) 114 (30.4–500) 0.012
CXCL5 566 (bd–5700) 1590 (425–4200) 0.004
CXCL8 41.0 (8.1–1220) 14.5 (1.69–37.8) ns
CXCL10 59.0 (7.0–590) 17.1 (9.16–57.6) ns
CXCL11 40.5 (bd–2690) bd (bd–167) ns
Immunomodulatory cytokines
TNFα 4.02 (bd–17.8) bd (bd–24.9) ns
IFNγ bd (bd–3.35) bd (bd–6.97) ns
CD40L 5830 (918–27,300) 2260 (264–14,700) 0.006
Growth factors
EGF 115 (bd–283) bd (bd–144) 0.011
VEGF 91.1 (17.1–191) 69.1 (bd–275) ns
TPO 497 (110–1770) 439 (154–2060) ns
HGF 290 (31.0–1610) 273 (91.7–634) ns
G-CSF 32.4 (bd–89.0) 38.7 (bd–140) ns
Leptin 4560 (622–54,700) 4750 (786–148,000) ns
Adhesion molecules
E-Selectin 28,600 (6770–107,000) 24,700 (8310–59,700) ns
P-Selectin 57,200 (18,100–126,000) 54,800 (21,400–94,800) ns
ICAM-1 239,000 (84,100–503,000) 303,000 (118,000–589,000) ns
VCAM-1 1,180,000 (553,000–4,540,000) 1,380,000 (870,000–2,770,000) ns
Matrix metalloproteinases and inhibitors
MMP-1 3820 (425–ad) 777 (184–ad) 0.003
MMP-2 45,900 (37,300–62,500) 44,700 (36,000–62,200) ns
MMP-3 12,500 (5240–ad) 12,100 (2720–ad) ns
MMP-7 4710 (993–28,400) 6100 (1640–31,100) ns
MMP-8 4260 (438–35,600) 4100 (350–24,100) ns
MMP-9 12,500 (1070–74,700) 5510 (1040–15,100) 0.010
MMP-12 8.20 (bd–38.3) 8.50 (bd–16.2) ns
TIMP-1 167,000 (98,400–257,000) 135,000 (91,000–245,000) ns
TIMP-2 119,000 (62,700–248,000) 102,000 (57,400–158,000) 0.006
TIMP-3 34,300 (bd–77,400) 9180 (bd–77,300) ns
TIMP-4 2120 (1110–3500) 1880 (1280–4170) ns
All mediators are given as pg/mL. The Mann–Whitney U test is used for comparison between low-risk and
high-risk MDS patients for each mediator and the corresponding p-values still significant after Bonferroni
correction are given in bold (p-values < 0.0013). FGF-basic. IL-2, IL-12, IL-17, and MMP-13 are not included in
the table as all or most serum levels of these mediators were undetectable. ad, above detection level; bd, below
detection level; ns, not significant.





































Figure 1. Serum levels of soluble mediators in myelodysplastic syndromes (MDS) patients,
a comparison of patients with low-risk (squares) and high-risk (triangles) disease. The figure presents
the overall results for those eight mediators showing statistically significant differences between the
two groups. The Mann–Whitney U test was used for comparison; p-values * p < 0.05, ** p < 0.01. CCL5
was the only mediator with a p-value lower than p = 0.0013, and considered significant following
Bonferroni correction.
2.1.2. Platelet Counts, Platelet-Derived Mediators and Serum Levels
Platelets contain several mediators that can be released during ex vivo handling of the samples [19].
Platelet counts were available only for 30 of our patients at the time of sampling. We observed
significant correlations between platelet counts and serum levels only for CD40L (Spearman correlation,
n = 30, r = 0.689, p < 0.001), CCL5 (r = 0.569, p = 0.001), CXCL5 (r = 0.371, p = 0.044), VEGF (r = 0.610,
p < 0.001), TPO (r = 0.435, p = 0.016), and P-selectin (r = 0.394, p = 0.031) when investigating the whole
group which was including both high- and low-risk patients. However, the platelet counts for the
low-risk patients were relatively high (median 175 ˆ 109/L, range 26–566) and when these 20 patients
were investigated separately we observed significant correlations between peripheral blood platelet
counts and CD40L (r = 0.751, p < 0.001), CCL5 (r = 0.652, p = 0.002), VEGF (r = 0.565, p = 0.009), TPO
(r = 0.516, p = 0.020), and P-selectin (r = 0.677, p = 0.001). No statistically significant correlations were
detected when the 10 high-risk patients were examined separately (median 66 ˆ 109/L, range 17–206).
These observations suggest that ex vivo platelet release may have a major impact on the serum levels
for these mediators.
2.1.3. The Overall Serum Mediator Profile Shows a Wide Variation in MDS Patients and Cannot
Distinguish between Low- and High-Risk Patients
To further visualize the differences in serum mediator profiles for our MDS patients we did
unsupervised hierarchical clustering analyses. The mediators that showed strong correlations between
serum levels and platelet counts (CD40L, CCL5, VEGF, and TPO) were left out from these analyses
together with those mediators that showed detectable levels in less than 10 samples. We first did
an analysis investigating serum levels of 37 soluble mediators from both patients and healthy controls
(Figure 2). The individuals then grouped into two major subsets/clusters; all of the healthy individuals
were included in the upper cluster and formed a distinct sub-cluster. The upper cluster also included
a heterogeneous group of MDS patients. This analysis clearly illustrates that there is a wide variation
in systemic cytokine profiles for MDS patients and a minority of patients even shows a profile very
similar to healthy individuals. However, an interesting observation is that five out of six patients
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intermingled between the controls are either RARS or RA with very good prognostic cytogenetics.
A major difference between the healthy individuals and patients was caused by compounds in the left
major cluster of mediators particularly IFN-γ, MMP-2, MMP-3 (leftmost cluster) and CXCL5, MMP-1,
and MMP-9. The lower cluster was mainly defined by higher levels of IL-1α, IL-5, and IL-13 (rightmost
cluster). Finally, the frequency of high-risk patients differed between the upper (patients 38, 26, 25, 43,
and 40) and lower patient clusters (patients 47, 11, 9, 6, 21, 18, 46, 45, and 19) (four out of 43 in the upper
cluster versus nine out of 25 in the lower cluster; χ-square test, p = 0.0158). A similar distribution of
high-risk patients between, and within, two main clusters was also seen when the clustering analysis
only included the patients (data not shown).
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Figure 2. Unsupervised hierarchical clustering of MDS patients and healthy controls. Parameters
where 10 or more sample values were above lowest detectable value were included in the clustering
analysis. Parameters closely correlated to platelet counts were also excluded from cluster analysis
(cluster of differentiation 40 ligand (CD40L), CCL5, vascular endothelial growth factor (VEGF), and
thrombopoietin (TPO)). All values w re median v ria ce standa dized and log(2)-t ansfo m d prior
to Euclidian distance clustering. Red-to-green gradi nt (see lower left part of the figure) represents
expression levels above or below the median serum levels for each individual parameter, respectively.
The classification systems that are used in the right part of the figure with regard to low/high
risk myelodysplastic syndromes (MDS) based on international prognostic scoring system (IPSS)
(Risk), World Health Organization classification (WHO), and cytogenetic abnormalities (Cytogen)
are also explained in the lower part of the figure. Risk: low-risk MDS patients—blue, high-risk
MDS patients—red, healthy controls—white. WHO subclasses: refractory cytopenia (RC)—turquoise,
refractory anemia with ring sideroblasts (RARS)—magenta, refractory cytopenia with multilineage
dysplasia (RCMD)—green, refractory cytopenia with multilineage dysplasia and ring sideroblasts
(RCMD-RS)—y llow, refractory anemia with excess blasts-1 (RAEB-1)—orange, RAEB-2—red, data
not available (NA)—white. Cytogenetics: very good—magenta, good—green, intermediate—yellow,
poor—orange, very poor—red, NA—white.
Int. J. Mol. Sci. 2016, 17, 1080 8 of 14
Finally, we performed a clustering analysis based only on five mediators that showed significant
differences between high- and low-risk patients, leaving out CCL5, CXCL5, and CD40L to exclude
a possible influence from ex vivo handling of samples (Figure 3). The patients were then separated
into two main clusters, and even though the use of this selection of biomarkers were able to group
high-risk patients to some extent (four out of 29 in the upper cluster versus 10 out of 19 in the lower
cluster; χ-square test, p = 0.0148) high-risk patients did not form separate sub-clusters. Taken together
with the overall mediator analysis in Figure 2 these last results show that there is a wide variation
between MDS patients with regard to their systemic mediator profile, and this variation seems without
strong relation to the high/low-risk classification.
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analysis was based on five mediators that showed statistically significant differences between the 
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Figure 3. Unsupervised hierarchical clustering analysis of high- and low-risk MDS patients.
The analysis was based on five mediators that showed statistically significant differences between
the two MDS subsets; we excluded the three mediators CCL5, CXCL5, and CD40L that also showed
significant differences but in addition showed significant correlations with platelet counts. All values
were median variance standardized and log(2)-transformed prior to Euclidian distance clustering.
Red-to-green gradient rep sen s xpression lev ls above or below the median serum levels for each
individual parameter, respectively. Each row repre en s one individual, and low-risk MDS patients are
marked with blue and high-risk MDS patients with red.
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2.1.4. Systemic Mediator Profiles Show Only Minor Variation over Time
We could compare the serum levels of soluble mediators at the time of diagnosis and 12 months
later for 24 unselected patients (16 low-risk and eight high-risk). Two of the low-risk patients then
experienced an increase in bone marrow blasts (1% versus 6.5% and 3% versus 9%, respectively), while
the other 14 had stable disease. Two of the high-risk patients transformed to AML before 12 months.
One of the low-risk patients and five of the high-risk patients were treated with 5-azacitidine in the
12 months period. When investigating all 24 patients together, the majority of the serum markers
were not significantly altered, the exceptions being decreased levels in the 12-month sample of leptin
(Wilcoxon’s signed ranks, n = 24, p = 0.005), MMP-2 (p = 0.018), TPO (p = 0.026), and ICAM-1 (p = 0.040).
When the low-risk patients were examined alone decreased leptin levels (n = 15, p = 0.008) could still
be detected and in addition VCAM-1 levels were significantly increased (p = 0.007), whereas analysis
of the high-risk patients alone showed increased MMP-3 levels (n = 8, p = 0.012). Thus, the systemic
mediator profiles showed only minor variation over time.
3. Discussion
The cytokine network is important in orchestrating immune responses, and previous studies
suggest that this network is dysregulated in MDS. However, the cytokine network interacts with
several other and biologically different immune mediators, e.g., soluble adhesion molecules and the
protease system [20,21]. Our study is the first to analyze the systemic (i.e., serum) profile of such
a broad range of biologically-heterogeneous soluble mediators in a relatively large group of unselected
MDS patients. Previous studies have shown conflicting results regarding systemic cytokine levels
in MDS. We observed a wide variation of the soluble mediator profile in serum from MDS patients
and this variation showed no strong association with the established prognostic classification of
MDS patients.
Our healthy controls were younger than the MDS patients, but two previous studies failed to
show any age-dependent differences between healthy individuals for a majority of the cytokines that
they examined [13,15]. One of these studies compared the levels of all cytokines included in our
present study in different age groups [13]. To the best of our knowledge it is not known whether
systemic levels of soluble adhesion molecules, MMPs, and TIMPs correlate with age. We, therefore,
solely compared serum cytokine levels for the MDS patients and our healthy controls in Table 1.
The levels of several soluble adhesion molecules and MMPs differed between our patients and
healthy controls and these adhesion molecules/MMPs did not show any correlation with age neither
for our patients (MMP-3 being the only exception), nor for the healthy controls. However, despite this,
we would emphasize that these results have to be interpreted with great care.
Only serum samples were available for our study, and platelets may then become activated
and release soluble mediators ex vivo during sample preparation with activation of the coagulation
system [19,22]. A significant correlation between serum mediator levels and peripheral blood platelet
counts would then be expected if this ex vivo release caused a significant contribution to the serum
levels, and this was observed only for a minority of the mediators examined in our study. On the other
hand, it would not be surprising if the true systemic in vivo levels of platelet-associated mediator
levels were correlated with the peripheral blood platelet counts, and this is also supported by studies
of plasma samples [19]. Whether one should leave out or include serum levels of platelet-derived
mediators in analyses of serum mediator profiles is, thus, controversial. For the clustering analysis in
the present study we either left out those mediators showing very strong correlations with platelet
counts (Figure 2) or we left out all showing significant correlations (Figure 3).
MMPs and their inhibitors should be regarded as immunoregulatory mediators and show several
interactions with the chemokine/cytokine system [21]. Very few previous studies have investigated
MMP expression in MDS [23–26], and these studies examined the intracellular expression or the
release during in vitro culture of bone marrow mononuclear cells. In contrast to the high release of
MMP-2 by bone marrow mononuclear cells described by Ries et al. [23] and Travaglino et al. [25] we
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observed decreased levels of MMP-2 in serum from MDS patients, and our present results thereby
suggest that MMP-2 release by non-myeloid cells and/or MMP-2 degradation/absorption are more
important for the systemic levels than the release by immature myeloid cells. Our observation that
MMP-1/3/9 serum levels correlate with neutrophil and lymphocyte peripheral blood counts are also
consistent with the hypothesis that the serum MMP levels reflect release by various cells. Former
observations regarding MMP-9 are heterogeneous; Messingerová et al. [26] observed increased MMP-9
levels in MDS patients with del(5q), and these levels normalized after treatment with lenalidomide,
Travaglino et al. [25] observed normal levels in MDS and decreased levels in patients with AML,
while Ries et al. [23] found decreased MMP-9 compared to healthy controls. These observations are
consistent with our present observations that there is a wide distribution range for MDS patients with
regard to MMP-9 levels. Travaglino et al. [25] observed inverse correlations between the frequency
of bone marrow blasts and release of MMP-2, as well as MMP-9 by myeloid cells. Observations
by Iwata et al. [24] also suggested reduced potential for MMP-9 induction in monocytes from MDS
patients with excess of blasts. These previous observations may explain our present observation of
lower MMP-2/3/9 serum levels in high-risk patients. Finally, MMP-7 serum levels were increased
in MDS patients and showed no correlation to peripheral blood cell counts. MMP-7 is involved
in cleavage of Fas ligands [27], and the increased levels may, thus, affect immune surveillance or
regulation of apoptosis in MDS patients.
The results from the two previous studies of soluble adhesion molecules in MDS are conflicting;
Südhoff et al. [28] found no difference between MDS patients and healthy controls, whereas
Passam et al. [29] reported increased systemic levels of both VCAM-1 and ICAM-1 and this increase
was most pronounced in high-risk disease. Both studies described significant correlations between
these adhesion molecule levels and peripheral blood monocyte counts, and Passam et al. [29].
in addition observed an association between high levels and adverse prognosis. We also detected
increased serum levels of VCAM-1 and ICAM-1 in MDS, and higher median levels in high-risk disease,
but we could not detect any association with prognosis based on IPSS scores. Of note, the overlap
between low- and high-risk groups for these adhesion molecules was greater than between MDS
patients and controls, and a lack of significant association is, thus, not likely to be caused by smaller
sample size.
We observed increased levels of CXCL8/IL-8 and CXCL10 in MDS compared to controls in our
cohort of unselected patients, and these chemokines clustered together in Figure 2. CXCL8/IL-8
is (i) a chemoattractant, primarily for neutrophils; and (ii) a pro-angiogenic factor [30]. CXCL8
has previously been described as the quantitatively-dominant pro-angiogenic factor in AML [31],
found to be increased in MDS and AML [32]. Further, release of CXCL8/IL8 has been found to be
increased when AML blasts are co-cultured with osteoblasts [33]. CXCL8/IL-8 binds the receptor
CXCR2 and the inhibition of this axis is proposed as a potentially specific therapeutic target in
MDS and AML [32]. Increased CXCL10 levels have also been detected in previous studies and has
been suggested as an independent poor prognostic factor [14]; our present results describing no
difference between low- and high-risk patients defined by the IPSS score is also consistent with
the hypothesis that CXCL10 levels have an independent prognostic impact. CXCL10 binds to the
CXCR3 chemokine receptor and acts as (i) a chemoattractant, particularly for Th1 and Tc1 effector
lymphocytes [34–36]; (ii) an angioregulatory mediator [37]; and (iii) a regulator of hematopoiesis [38].
The previously-described increased expression of CXCR3 mRNA both in peripheral blood and bone
marrow mononuclear cells further support a role of CXCL10 in the pathogenesis of MDS [39].
4. Materials and Methods
4.1. Patients
The study was approved by the Regional Ethics Committee (REK vest; REK number 3.2008.409),
and samples were collected after written informed consent. Serum samples were collected at the time
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of diagnosis for 49 patients (35 low-risk and 14 high-risk) (Supplementary Table S1), and a second
sample was collected one year later for 24 of them (16 low-risk, eight high-risk). The male/female
ratio for the MDS patients were 3.1:1 and the median age was 74 years (54–93). Serum samples from
23 healthy individuals were also collected (male/female ratio 0.6:1, median age 38 years (26–68)).
Haukeland University Hospital (Bergen, Norway) is the primary hospital for a defined geographic
area and our patient population represents an unselected/consecutive group of MDS patients from this
single institution. Patients were risk-stratified according to the international prognostic scoring system
(IPSS) [3], and patients with classification as low and intermediate-1 IPSS were grouped together as
low-risk, while intermediate-2 and high IPSS classification are referred to as high-risk. Three patients
who scored as intermediate-1 IPSS, were included in the high-risk group as patient one (patient 18, see
Supplementary Table S1) showed clinical progression with increasing BM blast counts (to 9%) and
increasing cytopenias following sampling, the second (patient 25) showed a rapid increase in bone
marrow blast counts (to 18%) within 10 weeks after sampling and the third patient (patient 40) had
a major discrepancy to international prognostic scorin system revised (IPSS-R) (score 4.0—intermediate
risk) and increasing bone marrow blast counts (to 6%) within 15 weeks of sampling.
4.2. Sample Preparation and Analysis
Peripheral blood samples were left to coagulate at room temperature for 60 min before
centrifugation (1300ˆ g for 10 min) and subsequent serum collection. Samples were stored
at ´80 ˝C until the levels of 47 soluble mediators were determined by Luminex analyses (R&D
Systems, Minneapolis, MN, USA): (i) the eleven interleukins IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6,
IL-10, IL-12p70(IL-12), IL-13, IL-17, and interleukin 1 receptor antagonist (IL-1ra); (ii) the nine
chemokines CCL-2/3/4/5/11, CXCL8/IL-8 and CXCL-5/10/11; (iii) the eight growth factors granulocyte
colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GM-CSF), VEGF,
TPO, EGF, fibroblast growth factor basic (FGF-B), HGF, and leptin; (iv) the three immunomodulatory
cytokines IFN-γ, CD40L, and TNF-α; (v) the four soluble adhesion molecules P-selectin, E-selectin,
ICAM-1, and VCAM-1; and (vi) the eight matrix metalloproteinases (MMP)-1/2/3/7/8/9/12/13
together with four tissue inhibitors of metalloproteinases (TIMP)-1/2/3/4. Six of these mediators
(FGF-B, GM-CSF, IL-2, IL-12, IL-17, and MMP-13) were undetectable for more than 90% of samples,
and were excluded from the analyses. Samples from 48 MDS patients (34 low-risk and 14 high-risk)
and 20 healthy individuals were analyzed for cytokine/chemokine and growth factor levels, whereas
samples from all 49 patients and 23 controls were analyzed for protease and adhesion molecule levels;
TIMP levels were not analyzed for the controls.
4.3. Statistical and Bioinformatical Analyses
Statistical analyses were performed using IBM SPSS (IBM Corp., Armonk, NY, USA) and
Graph Pad Prism (GraphPad Software, La Jolla, CA, USA, used for analysis of paired samples).
Mann–Whitney U test was used when comparing non-parametric values. Paired samples were
analyzed using Wilcoxon’s signed ranks test. Correlation analysis for nonparametric values was
performed using Spearman’s test. p-Values below 0.05 were considered significant. Bioinformatical
analyses were performed using J-Express (MolMine AS, Bergen, Norway) [40]. For unsupervised
hierarchical clustering all values were median variance standardized and log(2)-transformed. Complete
linkage was used as linkage method, and for distance measured, the Euclidian correlation was used.
5. Conclusions
To conclude, we investigated the systemic/serum profile of 47 biologically different soluble
immune mediators (i.e., cytokines/chemokines, soluble adhesion molecules, proteases and their
inhibitors) for a cohort of unselected MDS patients, and we describe: (i) differences between MDS
patients and healthy individuals for several of these biologically different mediators but, at the same
time, a considerable heterogeneity within the MDS cohort with regard to their serum profile of soluble
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immune mediators; (ii) this wide variation is seen both for patients with low- and high-risk disease,
(iii) low- and high-risk patients differ only for a minority of these mediators; and (iv) this mediator
profile is relatively stable over time in the individual patient, and this seems to be true even for patients
with disease progression requiring treatment with hypomethylating agents. Based on our present
results we suggest that the possible prognostic or predictive impact of the systemic profile of soluble
immune mediators should be further investigated in future clinical studies.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/17/7/
1080/s1.
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